[Expert consensus on subcutaneous cluster immunotherapy of inhaled allergens].

Abstract

Allergen-specific immunotherapy is the only etiological treatment that can prevent the progression of allergic diseases at present. Cluster immunotherapy is an improved immunotherapy regimen, which shortens the dose escalation period from 4-6 months in conventional regimen to 1-8 weeks. In the past, there was no consensus or guideline to guide the standardized application of subcutaneous cluster immunotherapy of inhaled allergens in China. Based on relevant research evidence at home and abroad and the opinions of industry experts, this consensus systematically expounded the indications and contraindications of cluster immunotherapy, and proposed that the cluster scheme took effect earlier than the conventional scheme, with similar incidence of systemic allergic reaction with the conventional scheme. At the same time, the risk factors and preventive measures of systemic allergic reaction caused by cluster immunotherapy were emphasized. This consensus aims to improve the understanding of cluster immunotherapy among medical staff in China and guide the standardized application and management of cluster immunotherapy.